Aktuellt
SENASTE
Redeye reviews Medivir's fourth quarter report, which presented another improvement of median time to progression for fostrox, now at 7 months. The way forward with the planned phase IIb study has also been updated after a type C meeting with the FDA.
LÄS MER
